{"filing":{"accession_number":"0001193125-26-282994","cik":"0001671858","ticker":"SPRY","company_name":"ARS Pharmaceuticals, Inc.","form":"8-K","filing_date":"2026-06-25","report_date":null,"primary_document":"d26870d8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1671858/000119312526282994/d26870d8k.htm"},"events":[{"id":13995,"run_id":12445,"accession_number":"0001193125-26-282994","anchor_item_number":"5.07","event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.98,"summary":"This is a clear Item 5.07 disclosure of shareholder vote results from ARS Pharmaceuticals' 2026 Annual Meeting held on June 24, 2026. The filing reports voting outcomes on four proposals: election of three Class III directors (Saqib Islam, Phillip Schneider, and Laura Shawver), ratification of Ernst \u0026 Young LLP as independent auditor, advisory approval of named executive officer compensation, and advisory vote on compensation vote frequency (determined to be annual). These are standard annual meeting matters that materially inform investors about board composition and governance preferences.","company_name":"ARS Pharmaceuticals, Inc.","ticker":"SPRY","filing_date":"2026-06-25","form":"8-K","submitted_at":null,"items":[{"id":11301,"accession_number":"0001193125-26-282994","item_number":"5.07","item_title":null,"event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.98,"reasoning":"This is a clear Item 5.07 disclosure of shareholder vote results from ARS Pharmaceuticals' 2026 Annual Meeting held on June 24, 2026. The filing reports voting outcomes on four proposals: election of three Class III directors (Saqib Islam, Phillip Schneider, and Laura Shawver), ratification of Ernst \u0026 Young LLP as independent auditor, advisory approval of named executive officer compensation, and advisory vote on compensation vote frequency (determined to be annual). These are standard annual meeting matters that materially inform investors about board composition and governance preferences.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-06-25T21:03:49.229407+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":11301,"accession_number":"0001193125-26-282994","item_number":"5.07","item_title":null,"event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.98,"reasoning":"This is a clear Item 5.07 disclosure of shareholder vote results from ARS Pharmaceuticals' 2026 Annual Meeting held on June 24, 2026. The filing reports voting outcomes on four proposals: election of three Class III directors (Saqib Islam, Phillip Schneider, and Laura Shawver), ratification of Ernst \u0026 Young LLP as independent auditor, advisory approval of named executive officer compensation, and advisory vote on compensation vote frequency (determined to be annual). These are standard annual meeting matters that materially inform investors about board composition and governance preferences.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-06-25T21:03:49.229407+00:00","company_name":"ARS Pharmaceuticals, Inc.","ticker":"SPRY","filing_date":"2026-06-25"}]}